These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin. MacGregor AB, Falk RE, Landi S, Ambus U, Samuel ES, Langer B. Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200 [Abstract] [Full Text] [Related]
3. Role of bacillus Calmette-Guérin in the treatment of advanced melanoma. Stewart JH, Levine EA. Expert Rev Anticancer Ther; 2011 Nov; 11(11):1671-6. PubMed ID: 22050015 [Abstract] [Full Text] [Related]
4. Adjuvant BCG immunotherapy for malignant melanoma. Paterson AH, Willans DJ, Jerry LM, Hanson J, McPherson TA. Can Med Assoc J; 1984 Oct 01; 131(7):744-8. PubMed ID: 6383591 [Abstract] [Full Text] [Related]
5. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G. J Clin Oncol; 1994 May 01; 12(5):1036-44. PubMed ID: 8164027 [Abstract] [Full Text] [Related]
6. Adjuvant BCG immunotherapy for stage I and II malignant melanoma. Silver HK, Ibrahim EM, Evers JA, Thomas JW, Murray RN, Spinelli JJ. Can Med Assoc J; 1983 Jun 01; 128(11):1291-5. PubMed ID: 6342739 [Abstract] [Full Text] [Related]
7. Oral bacille Calmette Guérin immunostimulation in malignant melanoma. MacGregor AB, Falk RE, Landi S, Ambus U, Langer B. Surg Gynecol Obstet; 1975 Nov 01; 141(5):747-54. PubMed ID: 1105837 [Abstract] [Full Text] [Related]
8. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy. de la Monte SM, Hutchins GM. Am J Dermatopathol; 1986 Aug 01; 8(4):331-5. PubMed ID: 3532854 [Abstract] [Full Text] [Related]
9. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. J Clin Oncol; 1991 Jul 01; 9(7):1151-6. PubMed ID: 2045856 [Abstract] [Full Text] [Related]
10. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Cancer; 2004 Apr 15; 100(8):1692-8. PubMed ID: 15073858 [Abstract] [Full Text] [Related]
18. The role of adjuvant therapy in melanoma management. Barth A, Morton DL. Cancer; 1995 Jan 15; 75(2 Suppl):726-34. PubMed ID: 7805001 [Abstract] [Full Text] [Related]
19. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma. Pinsky CM, Hirshaut Y, Wanebo HJ, Fortner JG, Miké V, Schottenfeld D, Oettgen HF. Ann N Y Acad Sci; 1976 Jan 15; 277(00):187-94. PubMed ID: 1069548 [No Abstract] [Full Text] [Related]
20. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke P. Eur J Cancer; 1993 Jan 15; 29A(9):1237-42. PubMed ID: 8343260 [Abstract] [Full Text] [Related] Page: [Next] [New Search]